Written question asked by Liz Twist (Labour) on Monday, 18 September 2023, in the House of Commons. It was due for an answer on Monday, 16 October 2023. It was answered by Will Quince (Conservative) on Monday, 16 October 2023 on behalf of the Department of Health and Social Care.
Adrenoleukodystrophy and Thalassaemia: Gene Therapies
- Question
-
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the withdrawal of Bluebird Bio from the (a) UK and (b) European market on access to gene therapy treatment for people with (i) beta thalassemia and (ii) cerebral adrenoleukodystrophy.
- Answer
-
No assessment has been made of the potential impact of the withdrawal of Bluebird Bio from the United Kingdom and European markets on access to gene therapy treatment for people with beta thalassemia and cerebral adrenoleukodystrophy. NHS England continues to make cost-effective treatments available to patients in England as determined by NICE’s technology appraisal and highly specialised technologies programmes.
Secondary information
- Type
- Written question
- Reference
- 200017
- Session
- 2022-23
- Subjects
- Thalassaemia Adrenoleukodystrophy Gene therapies
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2023-10-16 16:22:47 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/200017
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/200017
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/200017